NPC recalls Albuterol Sulfate Inhalation Solution

NewsGuard 100/100 Score

Nephron Pharmaceuticals Corporation (NPC) has initiated a voluntary recall, at the retail level, as a precautionary measure, due to results from our internal monitoring processes.  NPC is asking retailers to remove the affected lots from store shelves and is asking consumers to discontinue use and dispose of any product they may have that is included in this recall. This voluntary recall will affect the following product:

Albuterol Sulfate Inhalation Solution, 0.083%, in the 25 count packaging configuration (NDC# 0487-9501-25)

Ten (10) lots have been identified as impacted by this recall:

A3A33A, A3A33B, A3A34A, A3A35A, A3A36A, A3A37A, A3A38A, A3A40A, A3A41A, and A3A42A

NPC performs aseptic process simulation as part of our internal processes to assure product quality. All of the lots listed above met and passed NPC's quality specifications at the time of manufacture.  NPC has received no reportable adverse drug events for any of the lots included in this recall.  Nevertheless, in accordance with published guidance regarding aseptic processing simulation from the Food and Drug Administration (FDA), NPC has decided to initiate this recall as a precautionary measure.  

No other NPC products or lots are impacted by this recall. 

We are ready to work with every affected customer to ensure that the recall is not disruptive for the supply of this important drug product.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients